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Summary We have investigated the modifying influence of 17-,B oestradiol (E2), on the cytotoxicity of
methotrexate (MTX) towards two cell lines derived from human breast carcinoma. E2 (10 -7M -10-6M)
significantly reduced the antimetabolic effects of the drug towards an E2 non-responsive cell line, MDA-
MB-436, whilst potentiating the action of MTX in an E2 responsive line, MCF-7. Similarly, E2 (10-6M)
partially reversed the anti-proliferative effects of MTX in the MDA-MB-436 line and potentiated growth
inhibition in the E2 responsive cells. This potentiation was not observed if E2 was replaced by the less
biologically active a-isomer. In both cell lines pharmacological concentrations of the E2 reduced intracellular
levels of MTX achieved during a 48h treatment period. The latter finding is consistent with the ability of E2
to protect MDA-MB-436 cells from the action of MTX. Potentiation of the effects of MTX towards MCF-7
cells occurs despite reduced intra-cellular drug levels.
Chemotherapy and oestrogen or anti-oestrogen
therapy are important treatments for breast cancer.
High response rates to endocrine manipulative
therapy have been reported when treatment is based
on oestrogen receptor status of the patient.
Consideration of the heterogeneous nature of breast
cancer with respect to steroid hormone receptor
content suggests that combined hormone and
cytotoxic drug therapy may be more beneficial than
either treatment alone. The first trials designed to
test the efficacy of combined therapy yielded
conflicting results (Brunner et al., 1977; Carter,
1981). Although the rationale for combined therapy
is largely based on the hypothesis that endocrine
therapy will selectively kill receptor positive cells
whilst cytotoxic drug treatment will kill those cells
uninfluenced by the hormonal environment, little is
known of the modulating influence of hormones on
the efficacy of cytotoxic drugs.
We have previously reported that pharmaco-
logical concentrations of 17-fl oestradiol (E2),
reduced the anti-metabolic and anti-proliferative
effects of methotrexate (MTX) towards an E2 non-
responsive human breast cancer cell line MDA-MB-
436, an effect which correlated with an E2 induced
reduction of intracellular MTX steady-state levels
(Clarke et al., 1983). These results contrast with an
earlier report which demonstrated that the
cytotoxicity of cytosine arabinoside towards the E2
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responsive cell line MCF-7 was enhanced by
physiological concentrations of the hormone
(Weichselbaum et al., 1978).
We have therefore extended our studies to
include an investigation of the modulating influence
of E2 on MTX toxicity towards the MCF-7 cell
line.
Materials and methods
Cell culture and treatment conditions
MDA-MB-436 cells were obtained from Flow
laboratories (Irvine, Scotland), and MCF-7 cells
were the gift of Dr. C.D. Green, Liverpool
University. MDA-MB-436 and MCF-7 cells were
routinely maintained in Liebowitz L-15 and Eagles
Modified Minimal Essential medium respectively.
Both media were supplemented with 5% foetal calf
serum, 100 IU ml- penicillin and 100pgml-1
streptomycin. Four days before treatment medium
was replaced by medium containing 5% serum
which had been stripped of endogenous steroids
using dextran coated charcoal. Approximately 104
cells were seeded into microwell culture dishes and
exposed to E2 or solvent (ethanol, 10lp1) for 24h
prior to a further 24h exposure to MTX in the
absence or presence of the hormone. The
antimetabolic effect of treatment was assessed by
determination of incorporation of [3H]-deoxyuridine
into DNA as previously described (Van den Berg &
Ball, 1972). Identically treated cells were assessed
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for their proliferative capacity by replacing drug
containing medium with fresh medium with or
without E2 and determining cell number after 6
days growth.
Determination ofintracellular MTX steady-state
levels
Intracellular levels of MTX were assessed during a
48 h exposure of cells to 10-7M [3H]-MTX (3, 5,7-
[3H]-MTX, Sp. act. 20Cimmol -1, Amersham
International). Cells(5X 10') were plated onto 5cm
petri dishes and exposed to labelled drug in the
presence or absence of 10-6M E2. At appropriate
times cells were removed, washed x 4 with isotonic
saline and the cell pellet dissolved in 5mM Tris-
HCl buffer, pH 7.4, containing 0.15 M NaCl,
10mMEDTA, 0.5% (w/v) sodium dodecylsulphate
and 0.02% sodium azide. Radioactivity was
determined by scintillation counting and
intracellular MTX expressed as fmol. MTXmg-1
protein.
Hormone receptor assays
E2 receptor content was determined using dextran
coated charcoal to separate free from receptor
bound [3H]-E2 (Shafie & Brookes, 1979). Proges-
terone receptor was assayed using the method
of Pilchon & Milgrom (1977). (2,4,5, 7-[3H]) E2
(Sp. act. >90Cimmol-1 and (1,2,6,7,16,17-[3H])
progesterone (Sp. act. > 100Cimmol-1) were
obtained from Amersham International.
Results
Table I compares the E2 and progesterone receptor
status of the MDA-MB-436 and MCF-7 cell lines.
The former line synthesises low levels of E2
receptor which is detectable in both cytoplasm and
nucleus. However E2 fails to induce the synthesis of
progesterone receptor and the cells are non-
responsive to E2 in terms of effects on DNA
synthesis or cell proliferation (Clarke et al., 1983).
This line therefore appears to possess defects distal
to the E2 receptor translocation step. Our results
confirm that the MCF-7 cell line synthesises high
levels of the E2 receptor which is functional by the
criterion of mediating synthesis of the progesterone
receptor. Furthermore exposure of MCF-7 cells to
a wide range of E2 concentrations results in
stimulation of incorporation of [3H]-UdR into
DNA (Figure 1).
Although [3H]-UdR incorporation is stimulated
in MCF-7 cells by E2, the hormone potentiated in
a dose-dependent manner the ability of MTX to
inhibit incorporation of this precursor into DNA
Table I Cytoplasmic oestrogen receptor
(CER), nuclear oestrogen receptor
(NER) and progesterone receptor (PGR)
content of the MDA-MB-436 and MCF-
7 cell lines.
Cell line
Receptor MDA-MB-436 MCF-7
CER 12 251
NER 6 150
PGR 0 21
Values are fmolmg-
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Figure 1 The influence of a 24h exposure to E2 on
incorporation of [3H]-deoxyuridine into DNA of
MCF-7 cells. Results are the mean of 4
determinations.
(Figure 2). In marked contrast, the same figure
shows that E2 exposure partially reversed MTX
induced inhibition of [3H]-UdR in the E2 non-
responsive cell line. In both cell lines E2
modulation of the antimetabolic effects of MTX
was significant at hormone concentrations of 10-7
and 10-6M (P<0.01), Student's paired t test).
Figure 3 shows that modification of the anti-
metabolic effect of MTX ultimately led to similar
modulation of the anti-proliferative action of the
drug. The MDA-MB-436 cell line is intrinsically
more sensitive to MTX than is the MCF-7 line.
Concentrations of the drug were chosen for each
line to result in approximately the same degree of
growth inhibition. At the two concentrations used
10-6M E2 significantly reversed the anti-
proliferative effect of MTX towards the E2 non-
responsive line whilst potentiating the drug's effect
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Figure 2 The effect of E2 on the inhibition of [3H]-
deoxyuridine incorporation resulting from a 24h
treatment with 10-8M MTX, (0) (MDA-MB-436)
and 5 x 10-8M MTX, (A) (MCF-7). Results are the
mean of 4 determinations.
on the E2 responsive line. In this experiment
increased growth inhibition in the MCF-7 line was
observed in the absence of any significant effect on
growth by E2 alone.
We have previously shown that the reversal of
the effects of MTX by E2 in the MDA-MB-436 line
is accompanied by a reduction in the steady state
level of the drug achieved intra-cellularly (Clarke et
al., 1983). Table II demonstrates that the intra-
cellular levels of MTX are significantly reduced 24
and 48 h from start of drug exposure (10-7M) in
both cell lines by 10-6M E2. Preliminary studies
have indicated that this effect of E2 may be related
to the hormone's ability to induce a decrease in cell
membrane fluidity as measured using a fluorescent
probe (data not shown).
Table II The effect of 10-6M E2 on the intra-cellular
levels of MTX achieved during exposure of cells to
10-7M [3H]-MTX
Intra cellular MTX
(fmolmg-1 protein)
Cell line 24h 48h
MCF-7 Control 3215 +82 3593 + 130
10-6M E2 2647+69 2817+37
(P<0.001) (P<0.001)
MDA-MB-436 Control 1003 +21 1345 +54
10-6M E2 918+53 1005+49
(P<0.01) (P<0.001)
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Figure 3 The effect of E2 (10-6M) on the
antiproliferative action of MTX towards MDA-MB-
436 and MCF-7 cells. Results are expressed as the
percentage increase in cell number 6 days after
treatment. (Ol) Control; (0) 10-6M E2; (U) MTX;
(a) MTX+10-6M E2.
Table III shows that substituting the poorly
oestrogenic a-isomer (aE2), for E2 failed to result in
potentiation of the anti-proliferative effects of MTX
towards MCF-7 cells. Despite a slight, although
non-significant, reduction in proliferative capacity
during continuous exposure to 10-6M aE2 alone,
the effects of MTX were unaltered in the presence
of the a-isomer. 10-6M aE2 alone significantly
inhibited proliferation of MDA-MB-436 cells
(Table III), whilst a combination of aE2 and MTX
resulted in partial reversal of the effect of the
antimetabolite, although, in contrast to the results
obtained with E2, this did not reach significance.
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Table III The effect of aE2 (10-6M) on the
antiproliferative action of MTX towards MDA-
MB-436 and MCF-7 cells.
% Change in cell no.
(day 0 to day 6)
MCF-7 MDA-MB-436
Control 712+ 104 425+35
l-06M aE2 550+70a 327+28b
MTX (1) 584+118 258+22
MTX (1)+aE2 546+ 114c 302+52c
MTX (2) 368+48 113+23
MTX (2)+ocE2 394+52c 132+10C
MTX (1) and MTX (2) are the lower and
higher doses of the drug respectively as de-
scribed in Figure 3.
ap>0.05 with respect to control
bP<0.01 with respect to control
CP>0.1 with respect to MTX treatment alone
(Student's "t" test).
Discussion
The results presented demonstrate that E2 exposure
can markedly influence the cytotoxicity of MTX
towards human breast cancer cells growing in vitro.
Furthermore E2 protects a non-E2 responsive
breast cancer cell line from the effects of MTX
whilst potentiating the drug's action towards an E2
responsive line. These modulating influences
become significant at pharmacological
concentrations of the hormone (10-6 M). It is
probable that the ability of 10-6M E2 to partially
reverse the anti-metabolic and anti-proliferative
effects of MTX in the MDA-MB-436 cell line
(Figures 2 and 3) is largely a consequence of the
hormone's ability to reduce intra-cellular steady
state MTX levels. These levels were reduced by 18
and 22% 24 and 48h after drug treatment
respectively (Table II). We are unable to fully
explain our findings that E2 potentiates the effects
of MTX in the MCF-7 cell line. Table II
demonstrates that 10-6M E2 co-treatment reduces
intracellular MTX levels in the E2 responsive line
to a similar extent to the observed in the MDA-MB
436 line. Nevertheless the net result of combined
drug-hormone treatment was increased MTX
toxicity (Figures 2 and 3). Weichselbaum et al.
(1978), reported that physiological concentrations
of E2 enhanced the anti-proliferative action of
cytosine arabinoside in MCF-7 cells. However, high
concentrations (10-7M) failed to produce this
effect, an observation consistent with the author's
findings that pharmacological concentrations of the
hormone slightly decreased cell proliferative rate.
Although we consistently observe marked
stimulation of the incorporation of DNA
precursors by a wide range of E2 concentrations
(Figure 1), the effect of E2 on cell proliferative rate
was somewhat variable. Although increased cell
growth has been observed under our experimental
conditions, Figure 3 shows that E2 potentiation of
MTX action can occur in the absence of any
demonstrable mitogenic effect of the hormone.
Considerable variation in the biological response of
MCF-7 cells to E2 has been reported and may
reflect the influence of culture conditions (Page et
al., 1983), growth rate (Jakesz et al., 1984), or the
existence of different sublines (Katzenellenbogen et
al., 1984). The ability of E2 to increase the anti-
metabolic and anti-proliferative action of MTX
towards the MCF-7 line reported here is therefore
unlikely to be solely the result of an E2 induced
increase in cell proliferative capacity. It is possible
that the increase in the rate of incorporation of
[3H]UdR into DNA of MCF-7 cells resulting from
E2 treatment (Figure 1) may reflect an increase in
the proportion of cells in S phase (Weichselbaum et
al., 1978), which might be expected to potentiate
the cytotoxicity of a phase specific agent such as
MTX. However it is equally possible that the
potentiation observed is a consequence of E2
induced perturbations of other biochemical
processes not here identified. Whatever the
potentiating mechanism involved it is clear that it is
sufficient to overcome the reduction of intracellular
MTX levels concurrently caused by the hormone.
The proposal that the modulating effects of E2
on MTX toxicity in MCF-7 cells are mediated via
the oestrogen receptor is supported by our
observation that aE2 fails to mimic the action of
the more biologically active #-isomer (Table III).
Unlike E2, the a-isomer fails to stimulate DNA
synthesis (Lippman et al., 1976) and we have found
that it is unable to reverse the effects of tamoxifen
in MCF-7 cells (unpublished observations).
We have previously suggested that the ability of
E2 to reduce intracellular MTX levels is unlikely to
be a receptor mediated event (Clarke et al., 1983).
In a separate study (manuscript in preparation) we
have observed that 10-6M E2 treatment results in
a decrease in membrane fluidity in both cell lines,
as determined by changes in the steady state
fluorescence of a membrane associated probe,
diphenylhexatriene. It is possible that such changes
in lipid packing might result in a decrease in
mobility of the MTX cell membrane transport
protein complex.
If the interactions between E2 and MTX
reported here occur in vivo then a combination of
drug and hormone in a predominantly receptor
negative tumour might be expected to decrease the
efficacy of MTX. Whilst the combination may be
of value in a receptor positive tumour, humanBREAST CANCER RESPONSE TO METHOTREXATE AND OESTRADIOL 369
breast cancer almost certainly consists of cell
populations heterogeneous with respect to E2
receptor content, and receptor content may change
during the course of treatment. The net result of
combination treatment of such tumours may
therefore be difficult to predict.
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